drugset / Trial / NCT02848300

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

NCT02848300

Phase 1 Completed 11 enrolled Allergan
NaSingle-groupOpen-labelBasic science

Summary

This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

Timeline

Start
2016-07
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 1 % Topical

Indications